The Moderna Vaccine IndexThese companies are selected for composition "Moderna Vaccine" because
1.developed the vaccine
2.suppliers
3.distribution chain
Weights are calculated by relative market cap.
Next report date
Report period
Q1 2024
EPS estimate
—
Revenue estimate
149.61 MCHF
2.993CHF
158.29 MCHF
770.84 MCHF
17.95 M
About LABORATORIOS FARMACEUTICOS ROVI S.A.
Sector
CEO
Juan López-Belmonte Encina
Headquarters
Madrid
Website
Employees (FY)
2.11 K
Founded
1946
ISIN
ES0157261019
FIGI
BBG00LVDP609
Laboratorios Farmaceúticos Rovi SA engages in the research, development, manufacture, and marketing of small molecule and specialty biologic drugs. It operates through the following business segments: Manufacturing, Marketing, and Other. The Manufacturing segment obtains its income from service contracts that relate to the finalization of the pharmaceutical product production process for external entities and the manufacture of products to be subsequently marketed by other group companies. The Marketing segment purchases and sells pharmaceutical products. The Other segment includes other services, research, and development activities that are not significant for the group. The company was founded on December 21, 1946 and is headquartered in Madrid, Spain.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 41L is 80.050 CHF — it has increased by 5.33% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange LABORAT FARMA ROVI stocks are traded under the ticker 41L.
LABORAT FARMA ROVI is going to release the next earnings report on May 8, 2024. Keep track of upcoming events with our Earnings Calendar.
41L stock is 5.06% volatile and has beta coefficient of 0.32. Check out the list of the most volatile stocks — is LABORAT FARMA ROVI there?
41L earnings for the last quarter are 0.16 CHF per share, whereas the estimation was 0.12 CHF resulting in a 36.36% surprise. The estimated earnings for the next quarter are 0.63 CHF per share. See more details about LABORAT FARMA ROVI earnings.
LABORAT FARMA ROVI revenue for the last quarter amounts to 207.15 M CHF despite the estimated figure of 203.77 M CHF. In the next quarter revenue is expected to reach 207.79 M CHF.
Yes, you can track LABORAT FARMA ROVI financials in yearly and quarterly reports right on TradingView.
41L stock hasn't changed in a week, the month change is a 5.33% rise, over the last year LABORAT FARMA ROVI has showed a 24.29% increase.
41L net income for the last quarter is 47.87 M CHF, while the quarter before that showed 50.50 M CHF of net income which accounts for −5.22% change. Track more LABORAT FARMA ROVI financial stats to get the full picture.
Today LABORAT FARMA ROVI has the market capitalization of 4.31 B, it has decreased by 1.41% over the last week.
Yes, 41L dividends are paid annually. The last dividend per share was 1.03 CHF. As of today, Dividend Yield (TTM)% is 1.23%. Tracking LABORAT FARMA ROVI dividends might help you take more informed decisions.
Like other stocks, 41L shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade LABORAT FARMA ROVI stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 28, 2024, the company has 2.11 K employees. See our rating of the largest employees — is LABORAT FARMA ROVI on this list?
We've gathered analysts' opinions on LABORAT FARMA ROVI future price: according to them, 41L price has a max estimate of 91.10 CHF and a min estimate of 58.77 CHF. Read a more detailed LABORAT FARMA ROVI forecast: see what analysts think of LABORAT FARMA ROVI and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. LABORAT FARMA ROVI EBITDA is 226.56 M CHF, and current EBITDA margin is 29.39%. See more stats in LABORAT FARMA ROVI financial statements.